GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (NAS:ALPN) » Definitions » Forward Rate of Return (Yacktman) %

Alpine Immune Sciences (Alpine Immune Sciences) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Alpine Immune Sciences Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Alpine Immune Sciences's forward rate of return for was 0.00%.

The historical rank and industry rank for Alpine Immune Sciences's Forward Rate of Return (Yacktman) % or its related term are showing as below:

During the past 12 years, Alpine Immune Sciences's highest Forward Rate of Return was 20.00. The lowest was 3.61. And the median was 20.00.

ALPN's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 11.43
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Alpine Immune Sciences Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Alpine Immune Sciences's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpine Immune Sciences Forward Rate of Return (Yacktman) % Chart

Alpine Immune Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alpine Immune Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alpine Immune Sciences's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Alpine Immune Sciences's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpine Immune Sciences's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's Forward Rate of Return (Yacktman) % falls into.



Alpine Immune Sciences Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Alpine Immune Sciences's Forward Rate of Return of Dec. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/19.06+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpine Immune Sciences  (NAS:ALPN) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Alpine Immune Sciences Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpine Immune Sciences (Alpine Immune Sciences) Business Description

Industry
Traded in Other Exchanges
Address
188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Executives
Mitchell Gold director, officer: Executive Chairman and CEO ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102
Peter A. Thompson director C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James Paul Rickey officer: Senior VP and CFO ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102
Xiangmin Cui director, 10 percent owner NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Wolfgang Dummer officer: Chief Medical Officer 5491 OPTICAL CT., SAN JOSE CA 95138
Remy Durand officer: Chief Business Officer C/O ALPINE IMMUNE SCIENCES, INC., 185 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98012
Jorn Drappa director C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Andrew Seth Sandler officer: Chief Medical Officer 1301 2ND AVE, SEATTLE WA 98101
Frazier Life Sciences Viii, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert E Conway director C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021
Christopher Peetz director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Decheng Capital China Life Sciences Usd Fund Iii, L.p. 10 percent owner UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
Alpine Immunosciences, L.p. 10 percent owner 600 STEWART STREET, SUITE 1503, SEATTLE WA 98101
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Alpine Immune Sciences (Alpine Immune Sciences) Headlines

From GuruFocus